CYP2C19 Genotyping

CYP2C19 acts on 5-10% of drugs in current clinical use. About 3-6% of individuals of European & African origin, as well as 13-23% of Asians, have a slow acting, poor metabolizer form of this enzyme. [31] However, there is wide variability among populations. For example, the percent of Polynesians who are poor metabolizers ranges from 38-79% depending on location.

CYP2C19 is an important drug metabolizing enzyme that catalyzes the biotransformation of many other clinically useful drugs including antidepressants, barbiturates, proton pump inhibitors, antimalarial, and antitumor drugs.

Genelex offers improved detection rates using extended CYP2C19 testing. CYP2C19 testing identifies 11 of the more common alleles (*2-*10,*12,*17) in PCR-multiplex format, providing increased sensitivity and quality performance. This CYP2C19 detection panel is the most extensive on the market and covers seven known poor metabolizer alleles and one known rapid metabolizer allele. Analytical specificity and sensitivity for detection of these mutations are >99%.

Indication for CYP2C19 Testing

For individuals with a personal or family history of adverse drug reactions to medications metabolized by CYP2C19. In these cases, it’s critical to confirm the presence of genotypes that affect the metabolism of drugs such as clopidogrel (Plavix®), that are metabolized by cytochrome CYP2C19.